Joos Beda, Fischer Marek, Kuster Herbert, Pillai Satish K, Wong Joseph K, Böni Jürg, Hirschel Bernard, Weber Rainer, Trkola Alexandra, Günthard Huldrych F
Department of Medicine, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, CH-8091 Zurich, Switzerland.
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16725-30. doi: 10.1073/pnas.0804192105. Epub 2008 Oct 20.
Rapid rebound of plasma viremia in patients after interruption of long-term combination antiretroviral therapy (cART) suggests persistence of low-level replicating cells or rapid reactivation of latently infected cells. To further characterize rebounding virus, we performed extensive longitudinal clonal evolutionary studies of HIV env C2-V3-C3 regions and exploited the temporal relationships of rebounding plasma viruses with regard to pretreatment sequences in 20 chronically HIV-1-infected patients having undergone multiple 2-week structured treatment interruptions (STI). Rebounding virus during the short STI was homogeneous, suggesting mono- or oligoclonal origin during reactivation. No evidence for a temporal structure of rebounding virus in regard to pretreatment sequences was found. Furthermore, expansion of distinct lineages at different STI cycles emerged. Together, these findings imply stochastic reactivation of different clones from long-lived latently infected cells rather than expansion of viral populations replicating at low levels. After treatment was stopped, diversity increased steadily, but pretreatment diversity was, on average, achieved only >2.5 years after the start of STI when marked divergence from preexisting quasispecies also emerged. In summary, our results argue against persistence of ongoing low-level replication in patients on suppressive cART. Furthermore, a prolonged delay in restoration of pretreatment viral diversity after treatment interruption demonstrates a surprisingly sustained evolutionary bottleneck induced by punctuated antiretroviral therapy.
长期联合抗逆转录病毒疗法(cART)中断后,患者血浆病毒血症迅速反弹,这表明存在低水平复制细胞的持续存在或潜伏感染细胞的快速重新激活。为了进一步表征反弹病毒,我们对20名接受多次为期2周的结构化治疗中断(STI)的慢性HIV-1感染患者的HIV env C2-V3-C3区域进行了广泛的纵向克隆进化研究,并利用了反弹血浆病毒与治疗前序列的时间关系。短期STI期间的反弹病毒是同质的,表明重新激活过程中起源于单克隆或寡克隆。未发现反弹病毒在治疗前序列方面存在时间结构的证据。此外,在不同的STI周期出现了不同谱系的扩展。总之,这些发现意味着来自长期潜伏感染细胞的不同克隆的随机重新激活,而不是低水平复制的病毒群体的扩展。治疗停止后,多样性稳步增加,但平均而言,直到STI开始>2.5年后才达到治疗前的多样性,此时也出现了与先前存在的准种的明显差异。总之,我们的结果反对在接受抑制性cART治疗的患者中持续存在低水平复制。此外,治疗中断后治疗前病毒多样性恢复的长期延迟表明,间断抗逆转录病毒疗法会导致出人意料的持续进化瓶颈。